{"entity":{"id":"paul-nathan","kind":"person","name":"Paul Nathan","aka":[],"tldr":"Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma.","summary":"Paul Nathan (Mount Vernon Cancer Centre) was principal investigator of IMCgp100-202, the randomised trial showing the gp100-directed bispecific T-cell engager tebentafusp improves overall survival in HLA-A*02:01-positive metastatic uveal melanoma, the first drug to do so and the first approved TCR-based therapy. He has led UK melanoma and renal trials and chairs national melanoma guideline groups.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp"}],"tags":["uveal-melanoma","bispecific","uk"],"related":[],"cancers":["uveal-melanoma","melanoma"],"sections":[],"technologies":["t-cell-engager"],"targets":["gp100","cd3"],"drugs":["tebentafusp"],"companies":[],"institutions":["mount-vernon-cancer-centre"],"pathways":[],"terms":[],"trials":["imcgp100-202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, Mount Vernon Cancer Centre, London","institutionId":"mount-vernon-cancer-centre","specialisms":["Uveal melanoma","Melanoma","Renal cell carcinoma","Bispecific T-cell engagers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp"}],"papers":[{"title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma (IMCgp100-202)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103485"},{"title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304753"}]},"route":"/people/paul-nathan/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/"}],"drug":[{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/"}],"institution":[{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","route":"/institutions/mount-vernon-cancer-centre/"}],"trial":[{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/"}]}}